This study combined pegylated IL-10 with FOLFOX in previously treated metastatic pancreatic cancer patients and, unfortunately, that did not result in improvement in survival outcomes, leading to further disappointment[61]. The gene discussed is IL10; the disease is pancreatic neoplasm.